Literature DB >> 12592625

Small bowel allografts maintained by administration of bombesin while under immunosuppression.

Taizo Furukawa1, Osamu Kimura, Seitetsu Go, Naomi Iwai.   

Abstract

BACKGROUND/
PURPOSE: The aim of this study was to determine if Bombesin (BBS) could help maintain the mucosal villus state in small bowel allografts without inducing acute rejection under immunosuppression.
METHODS: Allogeneic small bowel transplantation was performed heterotopically in rats (n = 12). All rats received daily administration of FK506 from postoperative day 0 to day 28. On postoperative day 14, rats were divided into 2 groups of 6 rats each, and administered BBS or normal saline as a control. After 2 weeks of treatment, the rats were killed, and the graft mucosal villus state was evaluated by H&E staining, and crypt cell proliferation analysis was performed using immunohistochemistry with proliferative cell nuclear antigen (PCNA).
RESULTS: Villi were thin, and villus blunting was marked in the control group. The BBS group showed that the villi of the grafts were well maintained, and the volume of the lamina propria mucosa was adequately preserved. The PCNA labeling index of crypt cells in the control group was 40.06 +/- 3.36 (mean +/- SD) and that in the BBS group was 61.02 +/- 4.27. There was a significant difference (P <.001) between the 2 groups.
CONCLUSIONS: BBS maintained allograft epithelial cells and the volume of the lamina propria intestinal mucosa, stimulating proliferation of crypt cells under immunosuppression without inducing acute rejection. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12592625     DOI: 10.1053/jpsu.2003.50016

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  1 in total

1.  Influence of liver nonparenchymal cell infusion combined with cyclosporin A on rejection of rat small bowel transplantation.

Authors:  Yan-Ling Yang; Ji-Peng Li; Ke-Feng Dou; Kai-Zong Li
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.